Risedronate in the treatment of paget's disease of bone: An open label, multicenter study

Ethel S. Siris, Arkadi A. Chines, Roy D Altman, Jacques P. Brown, C. Conrad Johnston, Robert Lang, Michael R. Mcclung, Lawrence E. Mallette, Paul D. Miller, Will G. Ryan, Frederick R. Singer, Joseph R. Tucci, Rachelle A. Eusebio, Pirow J. Bekker

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

An open-label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men, 60 postmenopausal women; mean age, 68 years) with moderate to severe Paget's disease of bone (mean serum alkaline phosphatase [ALP] approximately seven times the upper limit of normal). Patients were treated with oral risedronate, 30 mg/day for 84 days, followed by 112 days without treatment. This 196-day cycle was repeated once if serum ALP did not normalize or increased from the nadir value by ≤25%. At the end of the first and second cycles, the mean percentage decreases for serum ALP were 65.7% and 69.1%, and for urinary hydroxyproline/creatinine 50.4% and 66.9%, respectively. The decreases from baseline in ALP and urinary hydroxyproline/creatinine were significant (p <0.001). Normalization of serum ALP was observed in 86 patients (53.8%): 53 during the first treatment cycle and 33 during the second. There was a significant proportion of patients reporting a decrease in the pagetic bone pain at days 84 and 196 (p <0.001). Overall, risedronate was well tolerated. Five patients withdrew due to adverse events, none of which were considered to be drug related. In conclusion, 30 mg of oral risedronate administered daily for 84 days significantly reduced the biochemical indices of disease activity and was associated with pain reduction in patients with moderate to severe Paget's disease of bone. Normalization of ALP was observed in the majority of patients. Repeated administration of risedronate was shown to be beneficial. In general, risedronate was well tolerated and demonstrated a good safety profile.

Original languageEnglish (US)
Pages (from-to)1032-1038
Number of pages7
JournalJournal of Bone and Mineral Research
Volume13
Issue number6
DOIs
StatePublished - Jun 1998

Fingerprint

Osteitis Deformans
Multicenter Studies
Alkaline Phosphatase
Hydroxyproline
Serum
Therapeutics
Creatinine
Safety
Pain
Diphosphonates
Risedronate Sodium
Bone and Bones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

Siris, E. S., Chines, A. A., Altman, R. D., Brown, J. P., Johnston, C. C., Lang, R., ... Bekker, P. J. (1998). Risedronate in the treatment of paget's disease of bone: An open label, multicenter study. Journal of Bone and Mineral Research, 13(6), 1032-1038. https://doi.org/10.1359/jbmr.1998.13.6.1032

Risedronate in the treatment of paget's disease of bone : An open label, multicenter study. / Siris, Ethel S.; Chines, Arkadi A.; Altman, Roy D; Brown, Jacques P.; Johnston, C. Conrad; Lang, Robert; Mcclung, Michael R.; Mallette, Lawrence E.; Miller, Paul D.; Ryan, Will G.; Singer, Frederick R.; Tucci, Joseph R.; Eusebio, Rachelle A.; Bekker, Pirow J.

In: Journal of Bone and Mineral Research, Vol. 13, No. 6, 06.1998, p. 1032-1038.

Research output: Contribution to journalArticle

Siris, ES, Chines, AA, Altman, RD, Brown, JP, Johnston, CC, Lang, R, Mcclung, MR, Mallette, LE, Miller, PD, Ryan, WG, Singer, FR, Tucci, JR, Eusebio, RA & Bekker, PJ 1998, 'Risedronate in the treatment of paget's disease of bone: An open label, multicenter study', Journal of Bone and Mineral Research, vol. 13, no. 6, pp. 1032-1038. https://doi.org/10.1359/jbmr.1998.13.6.1032
Siris, Ethel S. ; Chines, Arkadi A. ; Altman, Roy D ; Brown, Jacques P. ; Johnston, C. Conrad ; Lang, Robert ; Mcclung, Michael R. ; Mallette, Lawrence E. ; Miller, Paul D. ; Ryan, Will G. ; Singer, Frederick R. ; Tucci, Joseph R. ; Eusebio, Rachelle A. ; Bekker, Pirow J. / Risedronate in the treatment of paget's disease of bone : An open label, multicenter study. In: Journal of Bone and Mineral Research. 1998 ; Vol. 13, No. 6. pp. 1032-1038.
@article{148b3cbc56d24ee2af969ed0208a1d59,
title = "Risedronate in the treatment of paget's disease of bone: An open label, multicenter study",
abstract = "An open-label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men, 60 postmenopausal women; mean age, 68 years) with moderate to severe Paget's disease of bone (mean serum alkaline phosphatase [ALP] approximately seven times the upper limit of normal). Patients were treated with oral risedronate, 30 mg/day for 84 days, followed by 112 days without treatment. This 196-day cycle was repeated once if serum ALP did not normalize or increased from the nadir value by ≤25{\%}. At the end of the first and second cycles, the mean percentage decreases for serum ALP were 65.7{\%} and 69.1{\%}, and for urinary hydroxyproline/creatinine 50.4{\%} and 66.9{\%}, respectively. The decreases from baseline in ALP and urinary hydroxyproline/creatinine were significant (p <0.001). Normalization of serum ALP was observed in 86 patients (53.8{\%}): 53 during the first treatment cycle and 33 during the second. There was a significant proportion of patients reporting a decrease in the pagetic bone pain at days 84 and 196 (p <0.001). Overall, risedronate was well tolerated. Five patients withdrew due to adverse events, none of which were considered to be drug related. In conclusion, 30 mg of oral risedronate administered daily for 84 days significantly reduced the biochemical indices of disease activity and was associated with pain reduction in patients with moderate to severe Paget's disease of bone. Normalization of ALP was observed in the majority of patients. Repeated administration of risedronate was shown to be beneficial. In general, risedronate was well tolerated and demonstrated a good safety profile.",
author = "Siris, {Ethel S.} and Chines, {Arkadi A.} and Altman, {Roy D} and Brown, {Jacques P.} and Johnston, {C. Conrad} and Robert Lang and Mcclung, {Michael R.} and Mallette, {Lawrence E.} and Miller, {Paul D.} and Ryan, {Will G.} and Singer, {Frederick R.} and Tucci, {Joseph R.} and Eusebio, {Rachelle A.} and Bekker, {Pirow J.}",
year = "1998",
month = "6",
doi = "10.1359/jbmr.1998.13.6.1032",
language = "English (US)",
volume = "13",
pages = "1032--1038",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Risedronate in the treatment of paget's disease of bone

T2 - An open label, multicenter study

AU - Siris, Ethel S.

AU - Chines, Arkadi A.

AU - Altman, Roy D

AU - Brown, Jacques P.

AU - Johnston, C. Conrad

AU - Lang, Robert

AU - Mcclung, Michael R.

AU - Mallette, Lawrence E.

AU - Miller, Paul D.

AU - Ryan, Will G.

AU - Singer, Frederick R.

AU - Tucci, Joseph R.

AU - Eusebio, Rachelle A.

AU - Bekker, Pirow J.

PY - 1998/6

Y1 - 1998/6

N2 - An open-label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men, 60 postmenopausal women; mean age, 68 years) with moderate to severe Paget's disease of bone (mean serum alkaline phosphatase [ALP] approximately seven times the upper limit of normal). Patients were treated with oral risedronate, 30 mg/day for 84 days, followed by 112 days without treatment. This 196-day cycle was repeated once if serum ALP did not normalize or increased from the nadir value by ≤25%. At the end of the first and second cycles, the mean percentage decreases for serum ALP were 65.7% and 69.1%, and for urinary hydroxyproline/creatinine 50.4% and 66.9%, respectively. The decreases from baseline in ALP and urinary hydroxyproline/creatinine were significant (p <0.001). Normalization of serum ALP was observed in 86 patients (53.8%): 53 during the first treatment cycle and 33 during the second. There was a significant proportion of patients reporting a decrease in the pagetic bone pain at days 84 and 196 (p <0.001). Overall, risedronate was well tolerated. Five patients withdrew due to adverse events, none of which were considered to be drug related. In conclusion, 30 mg of oral risedronate administered daily for 84 days significantly reduced the biochemical indices of disease activity and was associated with pain reduction in patients with moderate to severe Paget's disease of bone. Normalization of ALP was observed in the majority of patients. Repeated administration of risedronate was shown to be beneficial. In general, risedronate was well tolerated and demonstrated a good safety profile.

AB - An open-label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men, 60 postmenopausal women; mean age, 68 years) with moderate to severe Paget's disease of bone (mean serum alkaline phosphatase [ALP] approximately seven times the upper limit of normal). Patients were treated with oral risedronate, 30 mg/day for 84 days, followed by 112 days without treatment. This 196-day cycle was repeated once if serum ALP did not normalize or increased from the nadir value by ≤25%. At the end of the first and second cycles, the mean percentage decreases for serum ALP were 65.7% and 69.1%, and for urinary hydroxyproline/creatinine 50.4% and 66.9%, respectively. The decreases from baseline in ALP and urinary hydroxyproline/creatinine were significant (p <0.001). Normalization of serum ALP was observed in 86 patients (53.8%): 53 during the first treatment cycle and 33 during the second. There was a significant proportion of patients reporting a decrease in the pagetic bone pain at days 84 and 196 (p <0.001). Overall, risedronate was well tolerated. Five patients withdrew due to adverse events, none of which were considered to be drug related. In conclusion, 30 mg of oral risedronate administered daily for 84 days significantly reduced the biochemical indices of disease activity and was associated with pain reduction in patients with moderate to severe Paget's disease of bone. Normalization of ALP was observed in the majority of patients. Repeated administration of risedronate was shown to be beneficial. In general, risedronate was well tolerated and demonstrated a good safety profile.

UR - http://www.scopus.com/inward/record.url?scp=15144345644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15144345644&partnerID=8YFLogxK

U2 - 10.1359/jbmr.1998.13.6.1032

DO - 10.1359/jbmr.1998.13.6.1032

M3 - Article

C2 - 9626635

AN - SCOPUS:15144345644

VL - 13

SP - 1032

EP - 1038

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 6

ER -